Table 1 Causes of anti-HIV first-line therapy discontinuation in the study population (n=1,096)
Type | Tot | Strata | n | % Over strata | % Over total |
|---|---|---|---|---|---|
Adverse events (toxicity/allergy) | 302 (1 death) | Gastrointestinal | 86 | 28.5% | 7.8% |
Hypersensitivity | 28 | 9.3% | 2.6% | ||
Central nervous system | 18 | 6.0% | 1.6% | ||
Hepatic | 14 | 4.6% | 1.3% | ||
Metabolic (glucose or lipid metabolism, lipodystrophy) | 34 | 11.3% | 3.1% | ||
Renal | 13 | 4.3% | 1.2% | ||
Hematologic | 40 | 13.2% | 3.6% | ||
Other | 69 | 22.8% | 6.3% | ||
Other causes | 618 | Simplification | 252 | 40.8% | 23.0% |
Patient’s choice | 93 | 15.0% | 8.5% | ||
Failure | 86 | 13.9% | 7.8% | ||
Regimen intensification | 59 | 9.5% | 5.4% | ||
Genotype-guided switch | 20 | 3.2% | 1.8% | ||
Low adherence | 19 | 3.1% | 1.7% | ||
End of pregnancy | 16 | 2.6% | 1.5% | ||
Structured interruption | 13 | 2.1% | 1.2% | ||
Enrolment in a new prospective study | 13 | 2.1% | 1.2% | ||
Pregnancy | 12 | 1.9% | 1.1% | ||
Other | 35 | 5.7% | 3.2% | ||
Non-discontinued | 176 (6 deaths) | N/A | 176 | 100% | 16.1% |